By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Oncolytics Biotech Inc. 

210-1167 Kensington Crescent

Calgary  Alberta  T2N 1X7  Canada
Phone: 403-670-7374 Fax: 403-283-0858



Company News
Oncolytics Biotech (ONC.TO) Announces Details Of 2017 Annual Meeting Of Shareholders 4/27/2017 11:12:02 AM
Oncolytics Biotech (ONC.TO) Announces Registration Pathway And Clinical Development Plan 4/12/2017 11:44:00 AM
Oncolytics Biotech (ONC.TO)’s REOLYSIN More Than Doubles Overall Survival in Patients With Mutated p53 Metastatic Breast Cancer 4/5/2017 7:02:58 AM
Oncolytics Biotech Inc. (ONC.TO)'s REOLYSIN Provides Statistically Significant Improvement In Overall Survival In Canadian Cancer Trials Group Sponsored Randomized Phase II Study In Metastatic Breast Cancer 4/3/2017 6:32:19 AM
Oncolytics Biotech Inc. (ONC.TO) Enters Into First-In-Class Collaboration With Myeloma UK And Celgene (CELG) Using REOLYSIN In Combination With Imnovid Or Revlimid In Patients With Myeloma 3/16/2017 6:45:09 AM
Oncolytics Biotech Inc. (ONC.TO) Announces 2016 Year-End Results 3/10/2017 8:42:40 AM
Oncolytics Biotech Inc. (ONC.TO) Release: Company Appoints Dr. Matt Coffey To The Role Of President And CEO 1/19/2017 7:59:38 AM
Oncolytics Biotech Inc. (ONC.TO) Announces Change To Board Of Directors 12/7/2016 7:00:51 AM
Oncolytics Biotech Inc. (ONC.TO) Collaborators Present Initial Results From REO 019 Study In Multiple Myeloma Combining REOLYSIN, Bortezomib And Dexamethasone At The American Society of Hematology Annual Meeting 12/6/2016 7:27:50 AM
Oncolytics Biotech Inc. (ONC.TO) Announces Appointment Of New Chief Medical Officer 11/10/2016 3:36:14 PM